Acquisition by Richard Levy of 6000 shares of Madrigal Pharmaceuticals at 111.06 subject to Rule 16b-3

MDGL Stock  USD 313.35  2.36  0.76%   
About 53% of Madrigal Pharmaceuticals' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Madrigal Pharmaceuticals suggests that some traders are interested. Madrigal Pharmaceuticals' investing sentiment shows overall attitude of investors towards Madrigal Pharmaceuticals.
  
Filed transaction by Madrigal Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 6000 common stock at 111.06 of Madrigal Pharmaceuticals by Richard Levy on 21st of April 2024. This event was filed by Madrigal Pharmaceuticals with SEC on 2024-04-01. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Madrigal Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Madrigal Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Madrigal Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Madrigal Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Madrigal Pharmaceuticals Historical Investor Sentiment

Investor biases related to Madrigal Pharmaceuticals' public news can be used to forecast risks associated with an investment in Madrigal. The trend in average sentiment can be used to explain how an investor holding Madrigal can time the market purely based on public headlines and social activities around Madrigal Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Madrigal Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Madrigal Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Madrigal Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals Fundamental Analysis

We analyze Madrigal Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Madrigal Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Madrigal Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Madrigal Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Madrigal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Madrigal Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Madrigal Pharmaceuticals Related Equities

XFORX4 Pharmaceuticals   10.23   
0%
100.0%
TGTXTG Therapeutics   7.43   
0%
72.0%
PLRXPliant Therapeutics   4.15   
0%
40.0%
ETNB89bio   1.65   
0%
16.0%
VKTXViking Therapeutics   0.43   
0%
4.0%
HEPAHepion Pharmaceuticals     
1.0%
0%
KRYSKrystal Biotech   0.39   
3.0%
0%
DAWNDay One   0.55   
5.0%
0%
TERNTerns Pharmaceuticals   0.86   
8.0%
0%
STOKStoke Therapeutics   0.90   
8.0%
0%
SRPTSarepta Therapeutics   0.94   
9.0%
0%
ABOSAcumen Pharmaceuticals   1.02   
9.0%
0%
PTCTPTC Therapeutics   1.15   
11.0%
0%
IOVAIovance Biotherapeutics   1.40   
13.0%
0%
ACLXArcellx   1.63   
15.0%
0%
INZYInozyme Pharma   3.31   
32.0%
0%
MREOMereo BioPharma   7.75   
75.0%
0%
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out Madrigal Pharmaceuticals Hype Analysis, Madrigal Pharmaceuticals Correlation and Madrigal Pharmaceuticals Performance.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.03)
Revenue Per Share
3.705
Return On Assets
(0.52)
Return On Equity
(1.30)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.